OraSure Technologies, Inc. Stock News

Prominent healthcare entrepreneur Ron Zwanziger warned on Monday he may pursue a more "adversarial path" if the OraSure Technologies board continues to resist his offer to buy the medical devices company, according to a letter seen by Reuters.

OraSure (OSUR) Q2 Revenue Falls 43%

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Carrie Eglinton Manner - President, CEO & Director Jason Michael Plagman - Vice President of Investor Relations Kenneth J. McGrath - Chief Financial Officer Conference Call Participants Noah Lewis - Raymond James & Associates, Inc., Research Division Operator Good day, and t...

BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.

OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisit...

BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025.

Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry.

The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research